Morgan Stanley reports 3.4% Zymeworks stake
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership of Zymeworks Inc. common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership of Zymeworks Inc. common stock. It reports beneficial ownership of 2,519,243 shares, representing 3.4% of the class as of 12/31/2025.
Morgan Stanley has shared voting power over 2,516,398 shares and shared dispositive power over 2,519,243 shares, with no sole voting or dispositive power. It states that it has ceased to be the beneficial owner of more than five percent of this class and that the securities are held in the ordinary course of business, not to change or influence control of Zymeworks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Zymeworks (ZYME) ownership level does Morgan Stanley report in this Schedule 13G/A?
Did Morgan Stanley own more than 5% of Zymeworks (ZYME) before this filing?
How much voting and dispositive power does Morgan Stanley report over Zymeworks (ZYME) shares?
What type of reporting person is Morgan Stanley in this Zymeworks (ZYME) Schedule 13G/A?
What is the event date and security class in Morgan Stanley’s Zymeworks (ZYME) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.